Fig. 5From: Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse StudyMonthly average number of days of any acute migraine medication use at baseline, month 1 and month 3 Back to article page